Mammary Cell News 10.49 December 13, 2018 | |
| |
TOP STORYThe anti-proliferative effects of the prototype of a new class of selective KDM5-inhibitors were evaluated in 40 cell lines, recapitulating the heterogeneity of breast cancer. [Oncogene] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Type I Interferon/IRF7 Axis Instigates Chemotherapy-Induced Immunological Dormancy in Breast Cancer Researchers provided experimental evidence that estrogen receptor negative breast cancer cells that survived high-dose doxorubicin and methotrexate based chemotherapies elicited a state of immunological dormancy. [Oncogene] Full Article Aggressiveness of Non-EMT Breast Cancer Cells Relies on FBXO11 Activity Through a loss-of-function screen, scientists found that a member of the E3 ubiquitin ligase complexes, FBXO11, specifically fueled tumor formation of a non-epithelial to mesenchymal transition (EMT)-like clone by restraining the p53/p21 pathway. [Mol Cancer] Full Article MMP14 Empowers Tumor-Initiating Breast Cancer Cells under Hypoxic Nutrient-Depleted Conditions Researchers investigated epithelial-to-mesenchymal transition and proteases in tumor-initiating cells (TICs) and their response to different environments by means of a newly generated immortalized TIC line. [FASEB J] Abstract TCDD induced circ_0001098 overexpression and then suppressed breast cancer tumorigenesis via miR-3942-3p/BARD1 axis. [Cell Cycle] Abstract Cordycepin administration promoted G2/M arrest and apoptosis of MCF-7 and MDA-MB-231 cells, restraining the proliferation of the cells in vitro and in vivo following irradiation. [Toxicol Appl Pharmacol] Abstract Scientists investigated the anti-metastatic and anti-epithelial-mesenchymal transition (EMT) properties of Antrodia salonea in TNBC cells. [Food Chem Toxicol] Abstract | Graphical Abstract Researchers found that a particular miRNA species, miR-181c, was significantly low-expressed in breast cancer cell line MCF-7, which developed chemoresistance towards doxorubicin than in the wild-type MCF-7 cells. [Int J Biol Macromol] Abstract Methylseleninic Acid Suppresses Breast Cancer Growth via the JAK2/STAT3 Pathway Investigators demonstrated by Cell Counting Kit-8 in mouse breast cancer cell line 4T1 that methylseleninic acid inhibited cell viability in a concentration-dependent and time-dependent manner. [Reprod Sci] Abstract Association of B7-H4, PD-L1, and Tumor Infiltrating Lymphocytes with Outcomes in Breast Cancer Scientists detected that B7-H4 protein was highly expressed in both breast cancer and stromal cells. Its expression was independent of breast cancer intrinsic subtypes. PD-L1 expression was higher in triple negative breast cancers. [npj Breast Cancer] Full Article Sox9 Regulates Cell State and Activity of Embryonic Mouse Mammary Progenitor Cells Targeted deletion of Sox9, from one clone, decreased the ability to respond to lactogenic stimuli, consistent with a previously identified role for Sox9 in regulating luminal progenitor function. [Commun Biol] Abstract Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSThe authors discuss the existing body of knowledge regarding the key functions of ceRNA networks (ceRNETs) and then highlight the emerging roles of some recently discovered ceRNETs in several hallmarks of breast cancer. [J Cell Physiol] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
INDUSTRY NEWSTrastuzumab-Resistant HER2 Positive Breast Cancer Reversed By Treatment with INB03 INmune Bio, Inc. announced that its lead drug candidate for treatment-resistant cancers, INB03â„¢, successfully inhibited the proliferation of tumor growth in pre-clinical models of trastuzumab treatment-resistant breast cancer. [INmune Bio, Inc.] Press Release OncoSec Medical Incorporated announced the presentation of new data that suggested treatment with tavokinogene telseplasmid had the ability to improve immune responses in heavily pretreated, inoperable and locally advanced triple negative breast cancers by increasing tumor infiltrating lymphocyte density, increasing effector cytokines, and upregulating immune-related gene expression. [OncoSec Medical Incorporated] Press Release Daiichi Sankyo Company, Limited announced that updated safety and efficacy data from the ongoing Phase I study with [fam-] trastuzumab deruxtecan, an investigational HER2 targeting antibody drug conjugate, were presented for a subgroup of patients with heavily pretreated HER2 low expressing metastatic breast cancer. [Daiichi Sankyo Company, Limited] Press Release Laboratory for Advanced Medicine announced new data validating results from its discovery of biomarkers to accurately detect breast cancer. [Laboratory for Advanced Medicine] Press Release | |
| |
POLICY NEWSThe End of DACA Would Be a Blow to Science With the end of Deferred Action for Childhood Arrivals (DACA), undocumented scientists will lose what few protections they currently have under immigrant law, lose their access to their scientific research, and once again live in fear, as they are caught in legal limbo. [Scientific American] Editorial South Korean Scientists Protest Treatment of University President Accused of Misusing Funds Researchers in South Korea have criticized the nation’s science ministry for its handling of an investigation into the president of the Korea Advanced Institute of Science and Technology (KAIST) in Daejon, the country’s top technical university. The science ministry alleges that KAIST leader Shin Sung-Chul made illegal payments to a California lab, but many scientists see a political purge. [Nature News] Editorial NIH Report Scrutinizes Role of China in Theft of U.S. Scientific Research Institutions across the U.S. may have fallen victim to a tiny fraction of foreign researchers who worked to feed American intellectual property to their home countries, an advisory committee to the National Institutes of Health (NIH) found in a report. [STAT News] Editorial
| |
EVENTSNEW 2019 ASCO Annual Meeting Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – Breast Cancer (Northwestern University) NEW Research Associate (University of Cambridge) Research Assistant – Breast Medical Oncology (MD Anderson Cancer Center) Associate Researcher – Breast Cancer Biology (Mount Sinai) Senior Coordinator – Breast Medical Oncology (MD Anderson Cancer Center) Research Fellow – Breast Cancer (International Iberian Nanotechnology Laboratory) Master’s Student – Stem Cell Biology and Cancer (Helmholtz-Center München) Faculty Position – Cancer Cell Signaling (The University of New Mexico Comprehensive Cancer Center) Postdoctoral Research Associate – Cell Based Assays (University of Oxford) Postdoctoral Associate – Molecular and Cell Biology (Baylor College of Medicine) Faculty Position – Cancer Pathobiology (University of Alabama at Birmingham) Postdoctoral Position – Novel Cancer Gene and Therapy (University of Notre Dame) Postdoctoral Fellow – Stem Cells and Cancer (Albert Einstein College of Medicine) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|